Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07531095 | Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) | PHASE1 | RECRUITING | 160 | — | — | Apr 21, 2026 | May 21, 2031 | May 29, 2026 | 6 | United States, Turkey (Türkiye) |
| Arm | Type | Description |
|---|---|---|
| Dose Exploration (Part 1) | EXPERIMENTAL | Multiple dose levels of ZL-1310 will be explored in combination with tarlatamab administered intravenously (IV). |
| Dose Expansion (Part 2) | EXPERIMENTAL | ZL-1310 will be administered IV at the selected maximum tolerated combination dose (MTCD) or recommended phase 2 dose (RP2D) in combination with tarlatamab administered IV. |
| Triplet Combination (Part 3) | EXPERIMENTAL | ZL-1310 will be administered at MTCD or RP2D in combination with tarlatamab and an anti-PD-L1 (durvalumab) each administered IV. |
| Name | Type | Description |
|---|---|---|
| ZL-1310 | DRUG | ZL-1310 will be administered as an IV infusion. |
| Tarlatamab | DRUG | Tarlatamab will be administered as an IV infusion. |
| Durvalumab | DRUG | Durvalumab will be administered as an IV infusion. |
Inclusion Criteria: * Age ≥ 18 years (or ≥ legal age within the country if it is older than 18 years) at the time of signing the informed consent. * Participants with Histologically or cytologically confirmed SCLC: * For Part 1, participants must have SCLC that has progressed or recurred following ...